Evidence map›Paper›PMID 35558642›Full record

ArticleRSC advances2019

Highly diastereoselective construction of novel dispiropyrrolo[2,1-

Sarra Boudriga, Saoussen Haddad, Moheddine Askri, Armand Soldera, Michael Knorr, Carsten Strohmann, Christopher Golz

Abstract read
In one paragraph

Article in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Pyrrolo[2,1-RSC advances · 2024
    Review
  2. Review
  3. Article
  4. Article
  5. Crystal structure of (1'Acta crystallographica. Section E, Crystallographic communications · 2020
    Article
  6. Article
  7. Synthesis of pyrrolidinedione-fused hexahydropyrrolo[2,1-Beilstein journal of organic chemistry · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sarra BoudrigaLaboratory of Heterocyclic Chemistry Natural Product and Reactivity/CHPNR, Department of Chemistry, Faculty of Science of Monastir 5000 Monastir Tunisia sarra_boudriga@yahoo.fr.ORCID https://orcid.org/0000-0002-4706-5181
Saoussen HaddadLaboratory of Heterocyclic Chemistry Natural Product and Reactivity/CHPNR, Department of Chemistry, Faculty of Science of Monastir 5000 Monastir Tunisia sarra_boudriga@yahoo.fr.
Moheddine AskriLaboratory of Heterocyclic Chemistry Natural Product and Reactivity/CHPNR, Department of Chemistry, Faculty of Science of Monastir 5000 Monastir Tunisia sarra_boudriga@yahoo.fr.ORCID https://orcid.org/0000-0002-9055-9769
Armand SolderaDepartement of Chemistry, Quebec Center for Functional Materials University of Sherbrooke Sherbrooke Quebec Canada J1K 2R1.
Michael KnorrInstitut UTINAM - UMR CNRS 6213, Université Bourgogne Franche-Comté 16 Route de Gray 25030 Besançon France.ORCID https://orcid.org/0000-0002-5647-8084
Carsten StrohmannTechnische Universität Dortmund, Anorganische Chemie Otto-Hahn-Strasse 6 44221 Dortmund Germany.
Christopher GolzTechnische Universität Dortmund, Anorganische Chemie Otto-Hahn-Strasse 6 44221 Dortmund Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the quest for new heterocyclic scaffolds exhibiting potentially biological activities for medicinal chemistry, a multicomponent 1,3-dipolar cycloaddition reaction of tetrahydroisoquinolinium

Identifiers

PMID35558642
PMCPMC9092959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.